Is There Enough Diversity in COVID Vaccine Test Subjects?
Is There Enough Diversity in COVID Vaccine Test Subjects?
SOLEDAD: THANKS FOR JOINING US FOR "MATTER OF FACT." A DOSE OF GOOD NEWS ABOUT POSSIBLE VACCINES FOR COVID-19. MODERN MODERN JOINED PFIZER IN ANNOUNCING STRONG RECALL RESULT FROM TESTING. BOTH VACCINES SHOW OVER-90% EFFECTIVENESS. AND BOTH ARE ON TRACK TO SEEK EMERGENCY USE AUTHORIZATION FROM THE F.D.A. WITH TRIALS MOVING FORWARD AT AN UNPRECEDENTED PACE THERE ARE QUESTIONS ABOUT THE DIVERSE DID YOU OF TEST SUBJECTS IN STPAEP TRIALS. FEDERAL DATA SHOW INFECTION RATESOR BLACK AND BROWN PEOPLE ARE TWO TO THREE TIMES HIGHER THAN WAIT PARES. DR. JAMES HILDRETH IS ONE OF THE LEADING IMMUNOLOGIST AND HEADS THE MEHARRY MEDICAL COLLEGE IN NASHVILLE THE LARGES PRIVATE INDEPENDENT HISTORICALLY BLACK ACADEMIC HEALTH SERVICE CENTER. DR. JAMES HILDRETH, IT IS NICE TO HAVE YOU BACK. THANK YOU FOR BEING WITH ME. WE AWAY SPOKE LAX YOU SAID YOU WOULD BE A CANDIDATE FOR THE VACCINE AND PART OF THAT WAS TO HELP RECRUIT MORE PEOPLE OF COLOR. HAS THAT WORKED AND BEEN THE RESPONSE MADE A DIFFERENCE? >> I THINK IT HAS MADE A DIFFERENCE BUT TO BE HONEST THERE'S A GREAT DEAL OF APPREHENSION IN PHAOURPT COMMUNITIES IN VACCINES AND MEDICAL RESEARCH GENERALLY. THAT IS WHY IT IS IMPORTANT FOR ME TO BE A PARTICIPANT IN THE TRIAL SO I CAN ADVOCATE FOR SOMETHING THAT I'M DOING MYSELF. THE APPROACH IS TO PROVIDE ENOUGH INFORMATION TO PEOPLE THAT THEY CAN MAKE THEIR OWN DECISION ABOUT WHETHER OR NOT THIS IS SOMETHING INSURE DID. PFIZER REPORTS 42% OF PARTICIPANT WERE FROM DIVERSE BACKGROUNDS AN HERE IN THE UNITED STATES 10% OF THE PARTICIPANTS WERE AFRICAN-AMERICAN. THAT IS TPNOT BEST BUT IT IS CERTAINLY A DESCENT REPRESENTATION OF MINORITIES IN THE STUDY. I THINK THAT GETTING ACADEMIC HEALTH CENTERS INVOLVE AND COMMUNITY ORGANIZATIONS HAS MADE A DEALERSHIPSMENT >> TRIAL YOU ARE INVOLVED WITH IS NOVAVAX TRIAL AND FAST TRACKED. CAN YOU EXPLAIN WHAT THAT MEANS. >> THAT MEANS THAT THE F.D.A. IS THE SOME CRITERIA THAT IF THEY ARE MET IT VACCINE CAN GET, INDICTED A FOR APPROVAL AND WILL GET AN E.U.A. AN MENTAL USE AUTHORIZATION AND THAT IS WHAT IS HAPPENING. NOW SOME PEOPLE WHO ARE PART OF THE VACCINE YOU A PREVIOUSLY PROCESS WOULD LIKE US TO JUST TO THE FULL APPROVAL AS OPPOSED TO E.U.A. BECAUSE THE STANDARD ARE A LITTLE MORE RIGOROUS. BUT GIVEN THE URGENT SUCCEED WHERE WE ARE I THINK THE E.U.A. EVALUATE IS APPROPRIATE. BUT PEOPLE NEED TO UNDERSTAND THAT DOESN'T MEAN THAT THEY WILL BE KPROEIZED. IT MEANS THAT SYSTEM OF STEPS NEEDED FOR YOU A PREVIOUSLY WOULD BE EXPEDITED. SOLEDAD: HOW DOES IT WORK BETWEEN DRUG COMPANIES? HOW WOULD YOU DESCRIBE THAT RELATIONSHIP AS YOU TRY TO CREATE A VACCINE THAT WORKS? >> WHAT HAS HAPPENED IS AN UP PRECEDENTED LEVEL OF COLLABORATION BETWEEN THE DRUG COMPANIES AND N. IMPLEMENT H. SO THEY ARE ALL TRYING TO GET TV VACCINES YOU A PROVED BUT THE LEVEL OF COOPERATION BETWEEN THE DRUG COMPANIES AND N.I.H. AND SOME OF THE PRIVATE CONTRACT AND RESEARCH ORGANIZATIONS IS UNPRECEDENTED. >> WHAT ARE YOUR WORSE OF THIS VACCINE BECOMING A POLITICAL FOOTBALL OR DO YOU THINK THAT WHEN IT ACTUALLY GETS TO SPRING, SUMMER, 2021 AWAY MIGHT BE THROUGH SOME OF THE MORE CONTENTIOUS POLITICAL PART OF IT DEBATE? >> MY FERVENT HOPE IS THAT THE VACCINES WILL NOT BECOME POLITICIZED BECAUSE THIS IS A PUBLIC HEALTH ISSUE, IT IS NOT A POLITICAL ISSUE AND THE TRUTH IS THAT NEED FOR THE VACCINE CONTENT BE JEFF STATED TO GET BACK TO A SENSE OF NORMALCY AROUND THE GLOBE. PEOPLE ARNOLD WORLD NEED VACCINE AND I THINK THAT WE NEED TO PLAN FOR THAT AND MAKING PROVISIONS FOR IT. I HOPE THAT IT WON'T BE BECOME POLITICIZED BUT WATCHING WHAT HAS HAPPENED WITH MAX AND OTHER THINGS I WORRY ABOUT THAT BUT I PRAY IN WON'T GO CASE M
Advertisement
Is There Enough Diversity in COVID Vaccine Test Subjects?
Drug makers Moderna and Pfizer announced this week that early test results show their respective COVID-19 vaccines to be more than 90% effective. Now, both are on track to request emergency authorization from the FDA. But even as scientists race to roll out a vaccine, there are questions about the diversity of the test subjects. Soledad O’Brien speaks with Dr. James E. K. Hildreth, one of the nation’s leading immunologists and head of the Meharry Medical College in Nashville.
Drug makers Moderna and Pfizer announced this week that early test results show their respective COVID-19 vaccines to be more than 90% effective. Now, both are on track to request emergency authorization from the FDA. But even as scientists race to roll out a vaccine, there are questions about the diversity of the test subjects. Soledad O’Brien speaks with Dr. James E. K. Hildreth, one of the nation’s leading immunologists and head of the Meharry Medical College in Nashville.
Advertisement